Effect of vaginal metronidazole + miconazole treatment during pregnancy for gestational age and birth weight in a population-based study.

Abstract

The objective of the study was to check the effect of the combination of metronidazole and miconazole (M+M) for the prevention of sexually transmitted infections/disorders related preterm delivery/birth. Antiprotozoal vaginal metronidazole was not able to prevent preterm birth, while the antifungal topical miconazole use showed some reduction in preterm birth in our previous studies. The population-based large control (without any defects) data set of the Hungarian Case-Control Surveillance System of Congenital Abnormalities was used for the evaluation of the combination of M+M for birth outcomes. Of 38,151 controls, 846 (2.2%) had treatment with vaginal tablet of M+M for vaginal infections. The prevalence of preterm birth was 9.5% after this treatment compared with the 9.2% of preterm birth in the untreated group. Thus the combination of M+M was not able to reduce the preterm birth associated with vulvovaginal infections/disorders.

• Authors: Zoltán Kazy, Erzsébet Puhó, Andrew E Czeizel
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 272 Issue 4 Pg. 294-7 (Oct 2005) ISSN: 0932-0067 [Print] Germany
• PMID: 16001192 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Metronidazole
• Miconazole

Topics

• Administration, Intravaginal
• Adult
• Antifungal Agents (administration & dosage)
• Birth Weight
• Case-Control Studies
• Female
• Gestational Age
• Humans
• Hungary
• Infant, Newborn
• Infant, Premature
• Metronidazole (administration & dosage)
• Miconazole (administration & dosage)
• Obstetric Labor, Premature (microbiology, prevention & control)
• Pregnancy
• Prospective Studies
• Retrospective Studies
• Sexually Transmitted Diseases (drug therapy, microbiology)
• Vaginal Diseases (drug therapy, microbiology)